Fred Alger Management, an investment management company, released its “Alger Small Cap Growth Fund” third quarter 2024 investor letter. A copy of the letter can be downloaded here. U.S. equities rose in the third quarter, driven by a dovish monetary policy shift from the Federal Reserve (Fed), and optimism around a soft economic landing. Class A shares of the fund underperformed the Russell 2000 Growth Index in the quarter. The Health Care and Consumer Discretionary sectors positively influenced performance, while Financials and Information Technology negatively impacted. In addition, you can check the fund’s top 5 holdings to determine its best picks for 2024.
Alger Small Cap Growth Fund highlighted stocks like CareDx, Inc (NASDAQ:CDNA) in the third quarter 2024 investor letter. Incorporated in 1998, CareDx, Inc (NASDAQ:CDNA) is involved in discovering, developing, and commercializing diagnostic solutions for transplant patients. The one-month return of CareDx, Inc (NASDAQ:CDNA) was 12.56%, and its shares gained 156.54% of their value over the last 52 weeks. On November 27, 2024, CareDx, Inc (NASDAQ:CDNA) stock closed at $24.91 per share with a market capitalization of $1.336 billion.
Alger Small Cap Growth Fund stated the following regarding CareDx, Inc (NASDAQ:CDNA) in its Q3 2024 investor letter:
“CareDx, Inc (NASDAQ:CDNA) is a specialty laboratory focused on developing and commercializing high-value diagnostic solutions for transplant patients. The company offers testing services, products, and digital healthcare solutions that support both pre- and post-transplant care. CareDx’s tests are used for post-transplant surveillance in heart, kidney, and lung transplants to detect signs of acute organ rejection. During the quarter, shares contributed to performance after the company reported strong fiscal second quarter revenues beat analyst estimates, driven by higher-than-anticipated reimbursement rates. Moreover, the Centers for Medicare and Medicaid Services (CMS) announced a favorable reimbursement coverage change in August, which the company expects could boost future revenue growth.”
A healthcare professional in front of a console, monitoring the progress of a transplant patient.
CareDx, Inc (NASDAQ:CDNA) is not on our list of 31 Most Popular Stocks Among Hedge Funds. As per our database, 24 hedge fund portfolios held CareDx, Inc (NASDAQ:CDNA) at the end of the third quarter which was 17 in the previous quarter. CareDx, Inc (NASDAQ:CDNA) reported revenue of $82.9 million in the third quarter, representing 23% year-over-year growth. While we acknowledge the potential of CareDx, Inc (NASDAQ:CDNA) as an investment, our conviction lies in the belief that AI stocks hold greater promise for delivering higher returns, and doing so within a shorter timeframe. If you are looking for an AI stock that is as promising as NVIDIA but that trades at less than 5 times its earnings, check out our report about the cheapest AI stock.
In another article, we discussed CareDx, Inc (NASDAQ:CDNA) and shared Baron Discovery Fund’s views on the company. In addition, please check out our hedge fund investor letters Q3 2024 page for more investor letters from hedge funds and other leading investors.
READ NEXT: Michael Burry Is Selling These Stocks and A New Dawn Is Coming to US Stocks.
Disclosure: None. This article is originally published at Insider Monkey.